Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Alpha-nicotinamide adenine dinucleotide (reduced form), abbreviated as α-NADH, is a variant of the NADH molecule in which the anomeric center of the ribosyldihydronicotinamide moiety has alpha configuration rather than the more common beta configuration[6][13]. NADH itself is a critical coenzyme in cellular metabolism, especially serving as an electron carrier during energy production in mitochondria, but α-NADH is a rare isomer with no established therapeutic target role or clinical significance[6][13][1][3]. The canonical biologically active species is the beta-NADH isomer, and α-NADH does not appear in standard biological redox reactions. Therefore, "α-NADH" is either a misapplied chemical name or reference: it is not a receptor, enzyme, transporter, or therapeutic target, and does not participate in pharmacological mechanisms.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Alpha-nicotinamide adenine dinucleotide (reduced form) (α-NADH).